| 0 |
ACETONAEMIC VOMITING |
1 |
0.0556 |
| 1 |
CONJUNCTIVAL PAPILLAE |
1 |
0.0500 |
| 2 |
ATOPIC KERATOCONJUNCTIVITIS |
1 |
0.0286 |
| 3 |
BULLOUS IMPETIGO |
1 |
0.0167 |
| 4 |
MEDIAN NERVE INJURY |
1 |
0.0161 |
| 5 |
CEREBROVASCULAR ARTERIOVENOUS MALFORMATION |
1 |
0.0115 |
| 6 |
ECZEMA HERPETICUM |
4 |
0.0086 |
| 7 |
DERMATOPHYTOSIS OF NAIL |
1 |
0.0084 |
| 8 |
ACQUIRED EPIDERMOLYSIS BULLOSA |
1 |
0.0081 |
| 9 |
ADMINISTRATION SITE IRRITATION |
1 |
0.0071 |
| 10 |
DYSHIDROTIC ECZEMA |
5 |
0.0070 |
| 11 |
GENERALISED PUSTULAR PSORIASIS |
2 |
0.0069 |
| 12 |
OROPHARYNGEAL OEDEMA |
1 |
0.0069 |
| 13 |
NEUROSYPHILIS |
1 |
0.0066 |
| 14 |
HERPES ZOSTER MENINGITIS |
1 |
0.0055 |
| 15 |
APPLICATION SITE HYPOAESTHESIA |
1 |
0.0043 |
| 16 |
HELMINTHIC INFECTION |
1 |
0.0041 |
| 17 |
OCULAR SURFACE DISEASE |
1 |
0.0036 |
| 18 |
ANAPLASTIC LARGE CELL LYMPHOMA T- AND NULL-CELL TYPES |
1 |
0.0034 |
| 19 |
DEFECT CONDUCTION INTRAVENTRICULAR |
1 |
0.0031 |
| 20 |
APPLICATION SITE OEDEMA |
1 |
0.0031 |
| 21 |
HAND DERMATITIS |
2 |
0.0029 |
| 22 |
TENOPLASTY |
1 |
0.0029 |
| 23 |
HERPES SIMPLEX REACTIVATION |
1 |
0.0026 |
| 24 |
LICHENIFICATION |
1 |
0.0024 |
| 25 |
CUTANEOUS T-CELL LYMPHOMA |
3 |
0.0024 |
| 26 |
ECZEMA NUMMULAR |
1 |
0.0020 |
| 27 |
APPLICATION SITE ACNE |
1 |
0.0020 |
| 28 |
APPLICATION SITE INFECTION |
1 |
0.0020 |
| 29 |
PALMOPLANTAR PUSTULOSIS |
1 |
0.0019 |
| 30 |
MOLLUSCUM CONTAGIOSUM |
1 |
0.0019 |
| 31 |
EOSINOPHIL PERCENTAGE INCREASED |
1 |
0.0018 |
| 32 |
NAIL DYSTROPHY |
1 |
0.0018 |
| 33 |
LYMPHOCYTE MORPHOLOGY ABNORMAL |
1 |
0.0017 |
| 34 |
CORNEAL PERFORATION |
1 |
0.0016 |
| 35 |
ACTIVITIES OF DAILY LIVING DECREASED |
1 |
0.0016 |
| 36 |
CUTANEOUS SYMPTOM |
1 |
0.0015 |
| 37 |
CYCLIC VOMITING SYNDROME |
1 |
0.0014 |
| 38 |
IMPETIGO |
2 |
0.0013 |
| 39 |
DISSEMINATED CRYPTOCOCCOSIS |
1 |
0.0013 |
| 40 |
LYMPHANGITIS |
1 |
0.0012 |
| 41 |
HAND-FOOT-AND-MOUTH DISEASE |
1 |
0.0012 |
| 42 |
VULVOVAGINAL ERYTHEMA |
1 |
0.0012 |
| 43 |
FOLLICULAR LYMPHOMA |
1 |
0.0011 |
| 44 |
PRODUCT INEFFECTIVE FOR UNAPPROVED USE |
3 |
0.0011 |
| 45 |
ANOGENITAL WARTS |
1 |
0.0011 |
| 46 |
DERMATITIS |
21 |
0.0010 |
| 47 |
BENIGN BREAST NEOPLASM |
1 |
0.0010 |
| 48 |
APPLICATION SITE PAPULES |
1 |
0.0009 |
| 49 |
HYDROCELE |
1 |
0.0009 |
| 50 |
SKIN EROSION |
3 |
0.0009 |
| 51 |
IDIOPATHIC URTICARIA |
1 |
0.0009 |
| 52 |
APPLICATION SITE SCAB |
2 |
0.0009 |
| 53 |
PNEUMONIA STREPTOCOCCAL |
1 |
0.0009 |
| 54 |
ERYTHEMA MULTIFORME |
8 |
0.0009 |
| 55 |
PUSTULE |
2 |
0.0008 |
| 56 |
APPLICATION SITE EROSION |
1 |
0.0008 |
| 57 |
HERPES OPHTHALMIC |
1 |
0.0008 |
| 58 |
MACULAR HOLE |
1 |
0.0007 |
| 59 |
CONJUNCTIVITIS ALLERGIC |
1 |
0.0007 |
| 60 |
PEMPHIGOID |
5 |
0.0007 |
| 61 |
MYELITIS |
1 |
0.0006 |
| 62 |
ONYCHOLYSIS |
1 |
0.0006 |
| 63 |
DERMATITIS EXFOLIATIVE GENERALISED |
2 |
0.0006 |
| 64 |
ALOPECIA AREATA |
1 |
0.0006 |
| 65 |
MONOPARESIS |
1 |
0.0006 |
| 66 |
DERMATITIS ATOPIC |
25 |
0.0005 |
| 67 |
INFECTION SUSCEPTIBILITY INCREASED |
1 |
0.0005 |
| 68 |
CORNEAL DISORDER |
1 |
0.0005 |
| 69 |
VARICELLA |
1 |
0.0004 |
| 70 |
GLOMERULONEPHRITIS |
1 |
0.0004 |
| 71 |
ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS |
1 |
0.0004 |
| 72 |
LUNG OPACITY |
1 |
0.0004 |
| 73 |
STRABISMUS |
1 |
0.0003 |
| 74 |
INJECTION SITE HYPERSENSITIVITY |
1 |
0.0003 |
| 75 |
EOSINOPHILIC PNEUMONIA |
1 |
0.0003 |
| 76 |
HERPES SIMPLEX |
2 |
0.0003 |
| 77 |
HEPATIC CYST |
1 |
0.0003 |
| 78 |
EAR PRURITUS |
1 |
0.0003 |
| 79 |
ERYTHEMA NODOSUM |
1 |
0.0003 |
| 80 |
CONJUNCTIVAL HYPERAEMIA |
1 |
0.0003 |
| 81 |
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE |
5 |
0.0003 |
| 82 |
TONGUE OEDEMA |
1 |
0.0003 |
| 83 |
SKIN FISSURES |
5 |
0.0003 |
| 84 |
BLEPHARITIS |
1 |
0.0002 |
| 85 |
ECZEMA |
13 |
0.0002 |
| 86 |
APPLICATION SITE DISCOLOURATION |
1 |
0.0002 |
| 87 |
APPLICATION SITE EXFOLIATION |
1 |
0.0002 |
| 88 |
LIP OEDEMA |
1 |
0.0002 |
| 89 |
PRODUCT USE IN UNAPPROVED INDICATION |
58 |
0.0002 |
| 90 |
TENSION HEADACHE |
1 |
0.0002 |
| 91 |
SKIN SWELLING |
2 |
0.0002 |
| 92 |
MONOPLEGIA |
1 |
0.0002 |
| 93 |
STAPHYLOCOCCAL BACTERAEMIA |
1 |
0.0002 |
| 94 |
PARONYCHIA |
1 |
0.0002 |
| 95 |
VIRAL UPPER RESPIRATORY TRACT INFECTION |
1 |
0.0002 |
| 96 |
APPLICATION SITE SWELLING |
1 |
0.0002 |
| 97 |
PRODUCT RESIDUE PRESENT |
1 |
0.0002 |
| 98 |
BURNING SENSATION |
13 |
0.0002 |
| 99 |
SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION |
3 |
0.0002 |
| 100 |
ENTEROCOLITIS |
1 |
0.0002 |
| 101 |
DERMATITIS ACNEIFORM |
1 |
0.0002 |
| 102 |
APPLICATION SITE VESICLES |
1 |
0.0002 |
| 103 |
MENINGITIS |
1 |
0.0001 |
| 104 |
EYE MOVEMENT DISORDER |
1 |
0.0001 |
| 105 |
NEPHROTIC SYNDROME |
1 |
0.0001 |
| 106 |
LARGE INTESTINE POLYP |
1 |
0.0001 |
| 107 |
PAPULE |
1 |
0.0001 |
| 108 |
SKIN BURNING SENSATION |
10 |
0.0001 |
| 109 |
AORTIC ANEURYSM |
1 |
0.0001 |
| 110 |
TRANSPLANT REJECTION |
1 |
0.0001 |
| 111 |
RHINITIS |
1 |
0.0001 |
| 112 |
SKIN EXFOLIATION |
10 |
0.0001 |
| 113 |
SKIN HYPERPIGMENTATION |
1 |
0.0001 |
| 114 |
DRUG ERUPTION |
2 |
0.0001 |
| 115 |
IRON DEFICIENCY ANAEMIA |
1 |
0.0001 |
| 116 |
CONJUNCTIVITIS |
2 |
0.0001 |
| 117 |
APPENDICITIS |
1 |
0.0001 |
| 118 |
HERPES ZOSTER |
6 |
0.0001 |
| 119 |
CELLULITIS |
5 |
0.0001 |
| 120 |
SUBARACHNOID HAEMORRHAGE |
1 |
0.0001 |
| 121 |
DRY SKIN |
13 |
0.0001 |
| 122 |
ERYTHEMA |
20 |
0.0001 |
| 123 |
PETECHIAE |
1 |
0.0001 |
| 124 |
INJECTION SITE NODULE |
1 |
0.0001 |
| 125 |
APPLICATION SITE PAIN |
2 |
0.0001 |
| 126 |
APPLICATION SITE PRURITUS |
2 |
0.0001 |
| 127 |
DERMATITIS CONTACT |
1 |
0.0001 |
| 128 |
SCAB |
1 |
0.0001 |
| 129 |
PRODUCT PRESCRIBING ERROR |
2 |
0.0001 |
| 130 |
RASH ERYTHEMATOUS |
4 |
0.0001 |
| 131 |
LOCALISED INFECTION |
2 |
0.0001 |
| 132 |
TENDON RUPTURE |
1 |
0.0001 |
| 133 |
GENERALISED OEDEMA |
1 |
0.0001 |
| 134 |
INJECTION SITE DISCOLOURATION |
1 |
0.0001 |
| 135 |
PRURITUS |
30 |
0.0001 |
| 136 |
MYDRIASIS |
1 |
0.0001 |
| 137 |
HIATUS HERNIA |
1 |
0.0001 |
| 138 |
INJECTION SITE INDURATION |
1 |
0.0001 |
| 139 |
APPLICATION SITE ERYTHEMA |
2 |
0.0001 |
| 140 |
UVEITIS |
1 |
0.0001 |
| 141 |
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION |
4 |
0.0001 |
| 142 |
APHONIA |
1 |
0.0001 |
| 143 |
SKIN REACTION |
1 |
0.0001 |
| 144 |
DRUG EFFECTIVE FOR UNAPPROVED INDICATION |
2 |
0.0001 |
| 145 |
DRUG EFFECT LESS THAN EXPECTED |
1 |
0.0001 |
| 146 |
IMMUNODEFICIENCY |
1 |
0.0001 |
| 147 |
BACK DISORDER |
1 |
0.0001 |
| 148 |
THERAPEUTIC RESPONSE SHORTENED |
2 |
0.0001 |
| 149 |
FUNGAL INFECTION |
2 |
0.0001 |
| 150 |
CANDIDA INFECTION |
1 |
0.0001 |
| 151 |
GASTROENTERITIS VIRAL |
1 |
0.0001 |
| 152 |
RASH PRURITIC |
3 |
0.0001 |
| 153 |
BACTERIAL INFECTION |
1 |
0.0001 |
| 154 |
PROTEINURIA |
1 |
0.0001 |
| 155 |
INJECTION SITE SWELLING |
4 |
0.0001 |
| 156 |
GLAUCOMA |
1 |
0.0001 |
| 157 |
THERAPEUTIC RESPONSE DECREASED |
3 |
0.0000 |
| 158 |
TOOTH LOSS |
1 |
0.0000 |
| 159 |
RASH PAPULAR |
1 |
0.0000 |
| 160 |
ADVERSE DRUG REACTION |
4 |
0.0000 |
| 161 |
HYPOGLYCAEMIA |
2 |
0.0000 |
| 162 |
RASH |
17 |
0.0000 |
| 163 |
SKIN ULCER |
1 |
0.0000 |
| 164 |
PAIN OF SKIN |
1 |
0.0000 |
| 165 |
PALLOR |
1 |
0.0000 |
| 166 |
BLISTER |
2 |
0.0000 |
| 167 |
BLOOD CREATINE PHOSPHOKINASE INCREASED |
1 |
0.0000 |
| 168 |
NASAL CONGESTION |
2 |
0.0000 |
| 169 |
LACRIMATION INCREASED |
1 |
0.0000 |
| 170 |
EPILEPSY |
1 |
0.0000 |
| 171 |
ADVERSE EVENT |
3 |
0.0000 |
| 172 |
OROPHARYNGEAL PAIN |
3 |
0.0000 |
| 173 |
LIMB DISCOMFORT |
1 |
0.0000 |
| 174 |
EYE DISORDER |
1 |
0.0000 |
| 175 |
VIRAL INFECTION |
1 |
0.0000 |
| 176 |
NEOPLASM MALIGNANT |
2 |
0.0000 |
| 177 |
EYE PRURITUS |
1 |
0.0000 |
| 178 |
RASH MACULAR |
1 |
0.0000 |
| 179 |
SLEEP DISORDER |
2 |
0.0000 |
| 180 |
THERAPEUTIC PRODUCT EFFECT INCOMPLETE |
2 |
0.0000 |
| 181 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
5 |
0.0000 |
| 182 |
ACCIDENTAL OVERDOSE |
1 |
0.0000 |
| 183 |
WHITE BLOOD CELL COUNT INCREASED |
1 |
0.0000 |
| 184 |
INJECTION SITE BRUISING |
2 |
0.0000 |
| 185 |
INJECTION SITE ERYTHEMA |
3 |
0.0000 |
| 186 |
URTICARIA |
4 |
0.0000 |
| 187 |
COLITIS ULCERATIVE |
1 |
0.0000 |
| 188 |
THERAPEUTIC PRODUCT EFFECT DECREASED |
1 |
0.0000 |
| 189 |
THERAPEUTIC RESPONSE UNEXPECTED |
1 |
0.0000 |
| 190 |
LOWER RESPIRATORY TRACT INFECTION |
1 |
0.0000 |
| 191 |
VISION BLURRED |
3 |
0.0000 |
| 192 |
SKIN IRRITATION |
1 |
0.0000 |
| 193 |
UPPER RESPIRATORY TRACT INFECTION |
1 |
0.0000 |
| 194 |
SWELLING |
2 |
0.0000 |
| 195 |
INTERSTITIAL LUNG DISEASE |
1 |
0.0000 |
| 196 |
PRODUCT DOSE OMISSION ISSUE |
6 |
0.0000 |
| 197 |
CONDITION AGGRAVATED |
6 |
0.0000 |
| 198 |
INJECTION SITE PAIN |
6 |
0.0000 |
| 199 |
THERAPY CESSATION |
1 |
0.0000 |
| 200 |
INFLAMMATION |
1 |
0.0000 |
| 201 |
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
1 |
0.0000 |
| 202 |
OEDEMA |
1 |
0.0000 |
| 203 |
HAEMATOCHEZIA |
1 |
0.0000 |
| 204 |
MUSCULAR WEAKNESS |
2 |
0.0000 |
| 205 |
URINARY TRACT INFECTION |
3 |
0.0000 |
| 206 |
BLADDER CANCER |
1 |
0.0000 |
| 207 |
CATARACT |
1 |
0.0000 |
| 208 |
DRUG INEFFECTIVE |
22 |
0.0000 |
| 209 |
PLEURAL EFFUSION |
1 |
0.0000 |
| 210 |
RHINORRHOEA |
1 |
0.0000 |
| 211 |
PSORIASIS |
2 |
0.0000 |
| 212 |
FEBRILE NEUTROPENIA |
1 |
0.0000 |
| 213 |
INJECTION SITE PRURITUS |
1 |
0.0000 |
| 214 |
DEVICE MALFUNCTION |
1 |
0.0000 |
| 215 |
HYPOAESTHESIA |
2 |
0.0000 |
| 216 |
ACNE |
1 |
0.0000 |
| 217 |
DIABETES MELLITUS |
1 |
0.0000 |
| 218 |
PERIPHERAL SWELLING |
2 |
0.0000 |
| 219 |
ARTHRITIS |
1 |
0.0000 |
| 220 |
PARAESTHESIA |
2 |
0.0000 |
| 221 |
CARDIAC FAILURE |
1 |
0.0000 |
| 222 |
THROMBOSIS |
1 |
0.0000 |
| 223 |
DRY MOUTH |
1 |
0.0000 |
| 224 |
TREATMENT FAILURE |
1 |
0.0000 |
| 225 |
RENAL IMPAIRMENT |
1 |
0.0000 |
| 226 |
PYREXIA |
4 |
0.0000 |
| 227 |
INTENTIONAL PRODUCT MISUSE |
1 |
0.0000 |
| 228 |
DEVICE ISSUE |
1 |
0.0000 |
| 229 |
ANXIETY |
3 |
0.0000 |
| 230 |
OFF LABEL USE |
9 |
0.0000 |
| 231 |
ATRIAL FIBRILLATION |
1 |
0.0000 |
| 232 |
ILLNESS |
1 |
0.0000 |
| 233 |
ACCIDENTAL EXPOSURE TO PRODUCT |
1 |
0.0000 |
| 234 |
HEADACHE |
6 |
0.0000 |
| 235 |
HAEMORRHAGE |
1 |
0.0000 |
| 236 |
MALAISE |
4 |
0.0000 |
| 237 |
ASTHMA |
1 |
0.0000 |
| 238 |
INCORRECT DOSE ADMINISTERED |
2 |
0.0000 |
| 239 |
CHILLS |
1 |
0.0000 |
| 240 |
OEDEMA PERIPHERAL |
1 |
0.0000 |
| 241 |
VISUAL IMPAIRMENT |
1 |
0.0000 |
| 242 |
DEHYDRATION |
1 |
0.0000 |
| 243 |
INFECTION |
1 |
0.0000 |
| 244 |
CEREBROVASCULAR ACCIDENT |
1 |
0.0000 |
| 245 |
MYALGIA |
1 |
0.0000 |
| 246 |
MYOCARDIAL INFARCTION |
1 |
0.0000 |
| 247 |
COVID-19 |
1 |
0.0000 |
| 248 |
NASOPHARYNGITIS |
1 |
0.0000 |
| 249 |
HYPERSENSITIVITY |
1 |
0.0000 |
| 250 |
PAIN |
3 |
0.0000 |
| 251 |
ARTHRALGIA |
2 |
0.0000 |
| 252 |
WEIGHT INCREASED |
1 |
0.0000 |
| 253 |
ABDOMINAL PAIN |
1 |
0.0000 |
| 254 |
DIZZINESS |
2 |
0.0000 |
| 255 |
INSOMNIA |
1 |
0.0000 |
| 256 |
COUGH |
1 |
0.0000 |
| 257 |
DYSPNOEA |
2 |
0.0000 |
| 258 |
DIARRHOEA |
2 |
0.0000 |
| 259 |
FATIGUE |
2 |
0.0000 |
| 260 |
NAUSEA |
2 |
0.0000 |
| 261 |
VOMITING |
1 |
0.0000 |